Trials / Active Not Recruiting
Active Not RecruitingNCT01848561
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 8,250 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
Conditions
Timeline
- Start date
- 2013-04-29
- Primary completion
- 2028-06-01
- Completion
- 2028-06-01
- First posted
- 2013-05-07
- Last updated
- 2025-07-16
Locations
512 sites across 21 countries: United States, Australia, Austria, Belgium, Canada, Croatia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Mexico, Netherlands, New Zealand, Norway, Puerto Rico, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT01848561. Inclusion in this directory is not an endorsement.